Table 2.
Summary table of results
| Measure | Comparison | Letter score increase | p‐value |
|---|---|---|---|
| BCVA letter score | BL to V1 | +5.90 | <0.001 |
| BCVA letter score | BL to V2 | +5.14 | <0.001 |
| Measure | Comparison | Log CS increase | p‐value |
| CS 1.5 CPD | BL to V1 | +0.102 | 0.0113 |
| CS 1.5 CPD | BL to V2 | +0.080 | 0.0558 |
| CS 3.0 CPD | BL to V1 | +0.109 | 0.0224 |
| CS 3.0 CPD | BL to V2 | +0.166 | 0.0155 |
| CS 6.0 CPD | BL to V1 | +0.117 | 0.0029 |
| CS 6.0 CPD | BL to V2 | +0.10 | 0.0360 |
| Measure | Comparison | mm3 decrease | p‐value |
| Drusen volume | BL to V1 | −0.024 | <0.001 |
| Drusen volume | BL to V2 | −0.029 | 0.0206 |
| Measure | Comparison | μm change | p‐value |
| Central drusen thickness | BL to V1 | −3.78 | <0.001 |
| Central drusen thickness | BL to V2 | −0.34 | 0.8781 |
| CRT | BL to V1 | −0.36 | 0.6872 |
| CRT | BL to V2 | 3.39 | 0.1422 |
| GA area | Comparison | mm change | p‐value |
| GA square root | BL to V1 | −0.021 | 0.2043 |
| GA square root | BL to V2 | 0.026 | 0.1618 |
| Measure | Comparison | mm3 decrease | p‐value |
| RV | BL to V1 | −0.066 | 0.1133 |
| RV | BL to V2 | −0.049 | 0.4639 |
BL = baseline, GA = geographic atrophy, early treatment diabetic retinopathy study letter score (BCVA = best‐corrected visual acuity), CS = contrast sensitivity at 1.5, 3.0 and 6.0 cycles per degree (CPD, log units), drusen volume reduction (mm3), central retinal drusen thickness (μm), retinal volume (RV, mm3) and central retinal thickness (CRT, μm).